Origin Endoscopy

Funding and NIH signals

• NIH award NIH awarded $1.21M (SBIR Phase II 1R44DK145328-01A1, new, notice Sep 14, 2026). NIH RePORTER 1R44DK145328-01A1 (Sep 14, 2026)
  Evidence (1 event)

  • Sep 14, 2026 · NIH RePORTER 1R44DK145328-01A1
    Organization: ORIGIN ENDOSCOPY INC.; City/State: BALTIMORE, MD; Project number: 1R44DK145328-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1212289; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals